You are here

CDMOs

$50M cell and viral vector manufacturing operation backed by Harvard

$50M cell and viral vector manufacturing operation backed by Harvard

Fierce Pharma

Flag link:

Shedding non-core units while loading up on cash, Mallinckrodt bags $250M in CDMO sale

Shedding non-core units while loading up on cash, Mallinckrodt bags $250M in CDMO sale

Endpoints

Flag link:

iBio Files for $30 Million Offering

iBio Files for $30 Million Offering

CP Wire

Flag link:

iBio Files for $30 Million Offering

Flag link:

Thermo Fisher to manufacture gene therapies being developed by Amicus

Thermo Fisher to manufacture gene therapies being developed by Amicus

Fierce Pharma

Amicus Therapeutics

Flag link:

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

Endpoints

Bristol-Myers Squibb

Flag link:

In 'golden age' for CDMOs, Thermo Fisher invests $150M in pharma services unit

In 'golden age' for CDMOs, Thermo Fisher invests $150M in pharma services unit

Biopharma Dive

Flag link:

3SBio snaps up Therapure CDMO for $290M

3SBio snaps up Therapure CDMO for $290M

BioPharma Dive

drug development

Flag link: